Volatile Anesthetics to Reduce Mortality in Cardiac Surgery
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
There is initial evidence that the choice of anesthesia can influence survival in the
specific setting of coronary artery bypass grafting surgery (CABG).
A recent international consensus conference included volatile agents among the few
drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and
that should be further studied. Volatile anesthetics (desflurane, isoflurane and sevoflurane)
have non-anesthetic pharmacological characteristics that confer cardiac protection when
compared to Total IntraVenous Anesthesia (TIVA). Several randomized controlled studies were
summarized in a meta-analysis that documented a reduction in perioperative cardiac troponin
release and mortality in patients receiving volatile anesthetics when compared to patients
receiving a TIVA. There are four published studies (Bignami et al. 2009) (De Hert et al.
2009) (Jackobsen et al. 2007) (Landoni et al. 2007) suggesting that these benefits can
translate into a reduced mortality rate in patients receiving volatile agents. The level of
evidence for these four studies is not high (one meta-regression, one underpowered randomized
controlled study, one retrospective study and one meta-analysis of small randomized studies)
and there is need for a large multicentre randomized controlled study to confirm these
findings, as suggested by the international consensus conference on this topic published in
2011 (Landoni et al 2011).
The purpose is to provide a large multicentre controlled randomized trial to demonstrate that
volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing CABG
(either with or without cardiopulmonary bypass).
The results of this study can support the use of volatile agents in all CABG procedures
worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis
that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be
reduced from 3% to 2% using volatile agents).